BCL2 and neoplasm: Obatoclax functions as a pan–BCL‐2 inhibitor that promotes apoptosis by neutralizing antiapoptotic proteins, while leflunomide suppresses tumor proliferation through inhibition of dihydroorotate dehydrogenase, thereby impairing pyrimidine synthesis and cell‐cycle progression [47, 48].